142121-93-5

Basic information

• Product Name: 4-FLUOROPHENYLGLYCINE-N-BOC PROTECTED
• Synonyms: N-BOC- 4-FLUOROPHENYLGLYCINE;Boc-aMino-(4-fluorophenyl)acetic acid;N-Boc-RS-4-Fluorophenylglycine
• CAS NO: 142121-93-5
• Molecular Formula: C₁₃H₁₆FNO₄
• Molecular Weight: 269.2704
• Mol File: 142121-93-5.mol

Chemical Properties

• Melting Point: 41-43 °C
• Boiling Point: 408.417°C at 760 mmHg
• Flash Point: 200.804°C
• Appearance: /
• Density: 1.243g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.52
• PKA: 3.47±0.10(Predicted)
• CAS DataBase Reference: 4-FLUOROPHENYLGLYCINE-N-BOC PROTECTED(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUOROPHENYLGLYCINE-N-BOC PROTECTED(142121-93-5)
• EPA Substance Registry System: 4-FLUOROPHENYLGLYCINE-N-BOC PROTECTED(142121-93-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 142121-93-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
4-Fluorophenylglycine-N-BOC protected is used as a building block for the synthesis and production of peptides and proteins, particularly pharmacologically active peptides. The N-BOC protective group ensures that the amino group does not react undesirably during the synthesis process, allowing for greater control over the specificity of reactions.
Used in Scientific Research:
In laboratory settings, 4-Fluorophenylglycine-N-BOC protected is used as a research tool for studying the properties and reactivity of fluorinated amino acids. Its unique structure and the presence of the N-BOC protective group make it an important compound for understanding the role of fluorine in peptide and protein chemistry.
Used in Drug Development:
4-Fluorophenylglycine-N-BOC protected is employed in the development of new drugs, particularly those targeting specific biological pathways or receptors. The incorporation of this compound into peptide or protein structures can potentially enhance the activity, selectivity, or stability of the resulting therapeutic agents, making it a valuable component in the design and synthesis of novel pharmaceuticals.

InChI:InChI=1/C13H16FNO4/c1-13(2,3)19-12(18)15-10(11(16)17)8-4-6-9(14)7-5-8/h4-7,10H,1-3H3,(H,15,18)(H,16,17)

Upstream product

• 124-38-9 carbon dioxide 
• 1358791-65-7 N-(tert-butoxycarbonyl)-α-(tributylstannyl)-4-fluorobenzylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7292-73-1 (2RS)-N-(p-fluorophenyl)glycine 
• 459-57-4 4-fluorobenzaldehyde 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 847147-38-0 [(2-benzoyl-4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-acryloylamino}-phenylcarbamoyl)-(4-fluoro-phenyl)-methyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Synthesis ofN-Boc-α-amino Acids from Carbon Dioxide by Electrochemical Carboxylation ofN-Boc-α-aminosulfones

Electrochemical reduction ofN-Boc-α-aminosulfones in DMF using an undivided cell equipped with a Pt plate cathode and an Mg rod anode under atmospheric pressure of bubbling carbon dioxide through the solution under constant current conditions resulted in a reductive C-S bond cleavage with elimination of benzenesulfinate ion generating the corresponding anion species followed by fixation of carbon dioxide to give the correspondingN-Boc-α-amino acids in moderate to good yields.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS

This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

HETEROARYL DERIVATIVES

Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to novel compounds of formula (I) which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS

The invention relates to novel compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

NOVEL COMPOUNDS

Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction.

Synthesis of arylglycine and mandelic acid derivatives through carboxylations of α-amido and α-acetoxy stannanes with carbon dioxide

Incorporation reactions of carbon dioxide (CO2) with N-Boc-α-amido and α-acetoxy stannanes were developed using CsF as a mild tin activator. Monoprotected α-amido stannanes could be used, and the corresponding arylglycine derivatives were obtained in moderate-to-high yields under 1 MPa (10 atm) of CO2 pressure. α-Acetoxy stannanes also underwent carboxylation to afford mandelic acid derivatives in excellent yields under ambient CO2 pressure. Both transformations enabled the synthesis of α-tertiary and α-quaternary carboxylic acid derivatives. In addition, the chirality of (S)-N-tert-butylsulfonyl-α- amido stannanes was transferred with up to 90% inversion of configuration at 100 °C.

GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF

Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.